Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles

References

• ABDEL -HAMEED, M. D., and KELLAWAY, I. W., 1997, Preparation and in vitro characterisation of mucoadhesive polymeric micro spheres as intra-nasal delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 44, 53–60.
   Google Scholar
• A6ABEYO6LU, I., 1981, Silrekli etki çoziinme kinetigine yeni bir denklem ye kinetik hesaplan icin bir bilgisayar program, Ulusal Eczacihk Kongresi, Istanbul.
   Google Scholar
• BULUT, P., and DiNcOL, F., 1991, Oksolamin sitrat ile tablet yardimci maddeleri arasmdaki geçimsizligin diferansiyel tarama kalorimetresi ile ara§tinlmasi. FABAD Farmasaik Bilimler Dergisi, 16, 209–214.
   Google Scholar
• CAGNOTTO, A., PAROTTI, L., and MENNINI, T., 1996, In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. European Journal of Pharmacology, 313, 63–67.
   PubMed Web of Science ®Google Scholar
• FTcl, K., HINCAL, A. A., KA.9, H. S., ERCAN, M. T., and RUACAN,1994, Microspheresof 5-fluorouracil using poly(DE-lactic acid): in vitro release properties and distribution in mice after I.V. administration. European Journal of Pharmaceutical Sciences, 1, 249–258.
   Google Scholar
• ENGEL, J., GRANERUS, A. K., and SVANBORG, A., 1975, Piribedil in Parkinson's syndrome: a clinical study. European Journal of Clinical Pharmacology, 8, 223–226.
   PubMed Web of Science ®Google Scholar
• FANELLI, R., and FRIGERIO, A., 1974, Determination of piribedil in biological materials by gas-liquid chromatography-mass fragmentography. Journal of Chromatography, 93, 441–446.
   PubMed Web of Science ®Google Scholar
• FREITAS, C., and MULLER, R. H., 1999, Stability determination of solid lipid nanoparticles (SLNTM) in aqueous dispersion after addition of electrolyte. Journal of Microencapsulation, 16, 59–71.
   PubMed Web of Science ®Google Scholar
• GATTEFOSSE, 1996, Specifications Sheet, Compritol® 888 ATO.
   Google Scholar
• GENTA, I., PAVANETTO, F., CONTI, B., GIUNCHEDI, P., and CONTI, U., 1995, Improvement of dexamethasone dissolution rate from spray-dried chitosan microspheres. S.T.P. Pharma Sciences, 5, 202–207.
   Google Scholar
• HALL, M. D., JENNER, P, and MARSDEN, C. D., 1983, Differential labelling of dopamine receptors in rat brain in vivo: comparison of (3H) piribedil, (3H) S 3608 and (3H) N,n-propylnorapomorphine. European Journal of Pharmacology, 87, 85–94.
   PubMed Web of Science ®Google Scholar
• HARKNESS, J. E., and WAGNER, J. E., 1995, The Biology and Medicine of Rabbits and Rodents, 4th edn (London: Williams and Wilkins), p. 28.
   Google Scholar
• KRIWET, B., and KISSEL, T., 1996, Poly(acrylic acid) microparticles widen the intercellular spaces of caco-2 shell monolayers: an examination by confocal laser scanning microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 42, 233–240.
   Web of Science ®Google Scholar
• LEGENDRE, J. Y., RAULT, I., PETIT, A., LUIJTEN, W., DEMUYNCK, I., HORVATH, S., GINOT, Y. M., and CUINE, A., 1995, Effects of 0-cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug S-9977. European Journal of Pharmaceutical Sciences, 3, 311–322.
   Web of Science ®Google Scholar
• MERCK INDEX, 1989, 11th edn (New Jersey, USA: Merck & Co., Inc.), p. 1190.
   Google Scholar
• MONTASTRUC, J. L., RASCOL, 0., and SENARD, J. M., 1993, Current status of dopamine agonists in Parkinson's disease management. Drugs, 46, 384–393.
   Google Scholar
• MULLER, R. H., and MEHNERT, W., 1995, Potential of solid lipid nanoparticles (SLN) for controlled drug delivery. Proceedings of 1st World Meeting APGIIAPV, Budapest, pp. 463–464.
   Google Scholar
• MULLER, R. H., MEHNERT, W., LUCKS, J. S., SCHWARZ, C., ZUR MÜHLEN, A., WEYHERS, H., FRErrAs, C., and Rum., D., 1995, Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 41, 62–69.
   Google Scholar
• MULLER, R. H., RUHL, D., RUNGE, S., SCHULZE-FORSTER, K., and MEHNERT, W., 1997, Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharmaceutical Research, 14, 458–462.
   Google Scholar
• PIGNATELLO, R., VANDELLI, M. A., GIUNCHEDI, P., and PUGLISI, G., 1997, Properties of tolmetin-loaded Eudragit RL 100 and Eudragit RS 100 microparticles prepared by different techniques. S.T.P. Pharma Sciences, 7, 148–157.
   Google Scholar
• PRIETO, M. J. B., FATTAL, E., GULIK, A., DEDIEU, J. C., ROQUES, B. P., and COUVREUR, P., 1997, Characterization and morphological analysis of a cholecystokinin derivative peptide-loaded poly(lactide-co-glycolide) microspheres prepared by a water-in-oil-in-water emulsion solvent evaporation method. Journal of Controlled Release, 43, 81–87.
   Web of Science ®Google Scholar
• SAHIN, I, TUNCER, M., and irmAN, M., 1990, Dopamine receptor agonists, N,N-dipropy1-2-aminotetralin (TL-68) and 2-di-n-propylamino-4,7-dimethoxyindane (RDS-127) antagonize oxotremorine-induced tremors by antimuscarinic action in mice. Archives Internationales de Physiologie et de Biochimie, 98, 7–9.
   PubMedGoogle Scholar
• S AKAKURA, C., TAKAHASHI, T. HAGIWARA, A., I TOH, M., SASABE, T., LEE, M., and S HOBAYASHI, S ., 1992, Controlled release of cisplatin from lactic acid oligomer microspheres incorporating cisplatin: in vitro studies. Journal of Controlled Release, 22, 69–74.
   Google Scholar
• S ARAT I, S., and CACCIA, S ., 1992, Solid-phase extraction of piribedil and its metabolites from plasma and urine without and after deconjugation, by high performance liquid chromatography. European Journal of Drug Metabolism and Pharmacokine tics, 17, 205–211.
   PubMed Web of Science ®Google Scholar
• S ARAT I, S., GUISO, G., GARATTINI, S., and CACCIA, S., 1991a, Kinetics of piribedil and effects on dopamine metabolism; hepatic biotransformation is not a determinant of its dopaminergic action in rats. Psychopharmacology, 105, 541–545.
   PubMed Web of Science ®Google Scholar
• S ARAT I, S., GUISO, G., SPINELLI, R., and CACCIA, S., 1991b, Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography. Journal of Chromatography, 563, 323–332.
   PubMed Web of Science ®Google Scholar
• S CHWARZ, C., MEHNERT, W., LUCKS, J. S., and MULLER, R. H., 1994, Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. Journal of Controlled Release, 30, 83–96.
   Web of Science ®Google Scholar
• S IEKMANN, B., and WESTESEN, K., 1994a, Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol I. Preparation and particle size determination. Pharmaceutical and Pharmacological Letters, 3, 194–197.
   Google Scholar
• S IEKMANN, B., and WESTESEN, K., 1994b, Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloids and Surfaces B: Biointerfaces, 3, 159–175.
   Google Scholar
• SjösTuöm, B., BERGENST AIM, B., and KRONBERG, B., 1993, A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions, II. Influence of the emulsifier, the solvent, and the drug substance. Journal of Pharmaceutical Sciences, 82, 584–589.
   PubMed Web of Science ®Google Scholar
• SWEET, R. D., WASTERLAIN, C. G., and McDowELL, F. H., 1974, Piribedil, a dopamine agonist, in Parkinson's disease. Clinical Pharmacology and Therapeutics, 16, 1077–1082.
   PubMed Web of Science ®Google Scholar
• TECHNOLOGIE SERVIER, 1995, Piribedil Lot/Batch No 48585, Company Specifications.
   Google Scholar
• TSAI, R. S ., EL -TAYAR, N., CARRUPT, P. A., and TESTA, B., 1992, Physicochemical and transport behaviour of piribedil: considerations of its membrane-crossing potential. International Journal of Pharmaceutics, 80, 39–49.
   Google Scholar
• U.S. PHARMACOPEIA NATIONAL FORMULARY, US PXXI I/NFXVII, 1990 (Easton: Mack Printing Company), pp. 1578–1579.
   Google Scholar
• VERONESE, F. M., MARSILIA, F. CALICET I, P. DE FILIPPIS, P., GIUNCHEDI, P., and LORA, S., 1998, Polyorganophosphazene microspheres for drug release: polymer synthesis, microsphere preparation in vitro and in vivo naproxen release. Journal of Controlled Release, 52, 227–237.
   PubMed Web of Science ®Google Scholar
• WAN, L. S. C., HENG, P. W. S., and CHAN, L. W., 1994, Surfactant effects on alginate microspheres. International Journal of Pharmaceutics, 103, 267–275.
   Web of Science ®Google Scholar
• WESTESEN, K., S IEKMAN, B., and Kocu, M. H. J., 1993, Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. International Journal of Pharmaceutics, 93, 189–199.
   Web of Science ®Google Scholar
• ZUR MÜHLEN, A., and MEHNERT, W., 1995, Drug incorporation and delivery of prednisolone loaded solid lipid nanoparticles. Proceedings of 1st World Meeting APGIIAPV, Budapest, pp. 455–456.
   Google Scholar